TriSalus Life Sciences Launches PREDICTT Clinical Trial for Drug Delivery in Liver Tumors
TriSalus Life Sciences has initiated patient enrollment for the PREDICTT clinical trial, aimed at assessing its Pressure-Enabled Drug Delivery (PEDD) technology in treating liver tumors. The trial represents an innovative approach to enhance drug delivery in patients with solid tumors.
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients w